3SBio Inc. (HKG:1530)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 56.85B +101.6% |
| Revenue (ttm) | 19.69B +94.3% |
| Net Income | 9.44B +305.8% |
| EPS | 3.82 +303.6% |
| Shares Out | 2.50B |
| PE Ratio | 5.96 |
| Forward PE | 17.70 |
| Dividend | 0.25 (1.10%) |
| Ex-Dividend Date | Jul 21, 2026 |
| Volume | 33,650,029 |
| Average Volume | 46,819,979 |
| Open | 22.58 |
| Previous Close | 22.76 |
| Day's Range | 21.80 - 22.58 |
| 52-Week Range | 10.94 - 36.80 |
| Beta | 0.59 |
| RSI | 44.12 |
| Earnings Date | Mar 30, 2026 |
About 3SBio
3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; and Cipterbin, an anti-HER2 monoclonal antibody for the treatment of advanced HER2-positive breast cancer and pan-HER2. It also offers Yisaipu, the receptor fusion tumor necrosis factor inhibitor; EPIAO and SEPO, an erythropoietin injection; Mandi-minoxidil, an OTC ex... [Read more]
Financial Performance
In 2025, 3SBio's revenue was 17.70 billion, an increase of 94.29% compared to the previous year's 9.11 billion. Earnings were 8.48 billion, an increase of 305.78%.
Financial numbers in CNY Financial StatementsNews
Mega Licensing Deal Boosts 3SBio Profits But Core Sales Slip
The Chinese drugmaker delivered sharply higher earnings, thanks to a bumper deal with Pfizer to develop a new cancer drug, but its older products came under pressure image credit: Bamboo Works Key Tak...